GTX INC | Business Contracts

First Amendment to the Amended and Restated License Agreement Between the University of Tennessee Research Foundation and the Registrant dated August 22, 2022 (Filed With SEC on November 3, 2022)

Description of Securities of the Registrant (Filed With SEC on March 10, 2022)

Form of Stock Option under the Inducement Plan (Filed With SEC on March 10, 2022)

2019 Incentive Award Plan of the Registrant effective June 7, 2019 (the 2019 Plan) (Filed With SEC on March 10, 2022)

Office Lease between Cognac Del Mar Owner II LLC and Registrant dated March 17, 2021 (Filed With SEC on May 6, 2021)

Amendment #4 to Collaboration Agreement between Oncternal Therapeutics, Inc. and The University of Texas M.D. Anderson Cancer Center, dated February 19, 2020 (Filed With SEC on August 6, 2020)

Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated April 30, 2019, by and among GTx, Oncternal and Merger Sub (Filed With SEC on April 30, 2019)

Amendment No. 2 to the Inducement Plan dated December 15, 2021 (Filed With SEC on March 10, 2022)

Form of Restricted Stock Unit under the 2019 Plan (Filed With SEC on March 10, 2022)

Form of Stock Option Agreement under the 2019 Plan (Filed With SEC on March 10, 2022)

Amended and Restated License Agreement between the University of Tennessee Research Foundation and the Registrant Oncternal Therapeutics, Inc. dated March 9, 2022 (Filed With SEC on March 10, 2022)

Open Market Sale Agreement (Filed With SEC on December 17, 2021)

First Amendment to Contingent Value Rights Agreement dated November 1, 2021 by and between the Registrant, Marc S. Hanover, as the Holders Representative, and Computershare Inc.,... (Filed With SEC on November 4, 2021)

Employment Agreement dated May 17, 2021 between Oncternal Therapeutics, Inc. and Salim Yazji, M.D (Filed With SEC on August 5, 2021)

Employment Agreement dated April 12, 2021 between Oncternal Therapeutics, Inc. and Chase Leavitt (Filed With SEC on August 5, 2021)

Amended and Restated Employment Agreement dated January 6, 2021 between Oncternal Therapeutics, Inc. and Raj Krishnan, Ph.D (Filed With SEC on August 5, 2021)

Amendment No. 1 to the Oncternal Therapeutics, Inc. 2021 Employment Inducement Incentive Award Plan (Filed With SEC on May 28, 2021)

Open Market Sale Agreement (Filed With SEC on May 28, 2021)

Employment Transition Agreement between Frank Hsu, M.D. and Registrant, dated February 24, 2021 (Filed With SEC on May 6, 2021)

Non-Employee Director Compensation Policy, as amended and restated, effective March 18, 2021 (Filed With SEC on May 6, 2021)

Amendment #3 to Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and the Regents of the University of California, dated February 5, 2021 (Filed With SEC on March 11, 2021)

Engagement Letter between the Registrant and H.C. Wainwright & Co., LLC, dated as of December 9, 2020 (Filed With SEC on March 11, 2021)

Oncternal Therapeutics, Inc. 2021 Employment Inducement Incentive Award Plan and form of stock option agreement thereunder (Filed With SEC on February 17, 2021)

Form of Underwriter Warrant (Filed With SEC on December 11, 2020)

Amended and Restated Underwriting Agreement, dated December 9, 2020, by and between Oncternal Therapeutics, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on December 11, 2020)

Form of Underwriter Warrant (Filed With SEC on November 19, 2020)

Amended and Restated Underwriting Agreement, dated November 17, 2020, by and between Oncternal Therapeutics, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on November 19, 2020)

Form of Underwriter Warrant (Filed With SEC on August 31, 2020)

Amended and Restated Underwriting Agreement, dated August 27, 2020, by and between Oncternal Therapeutics, Inc. and H.C. Wainwright & Co., LLC (Filed With SEC on August 31, 2020)

Form of Securities Purchase Agreement (Filed With SEC on July 21, 2020)

Form of Warrant (Filed With SEC on July 21, 2020)

Form of Placement Agent Warrant (Filed With SEC on July 21, 2020)

Engagement Letter between Oncternal Therapeutics, Inc. and H.C. Wainwright & Co., LLC, dated as of May 15, 2020 (Filed With SEC on May 21, 2020)

Form of Warrant (Filed With SEC on May 21, 2020)

Form of Placement Agent Warrant (Filed With SEC on May 21, 2020)

Form of Securities Purchase Agreement (Filed With SEC on May 21, 2020)

Description of Securities of Oncternal Therapeutics, Inc (Filed With SEC on March 16, 2020)

Consulting Agreement dated September 20, 2019 between Robert J. Wills. Ph.D. and Oncternal Therapeutics, Inc (Filed With SEC on March 16, 2020)

Form of Indemnification Agreement (Filed With SEC on March 16, 2020)

Amendment #2 to Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and the Regents of the University of California, dated May 15, 2019 (Filed With SEC on March 16, 2020)

Amendment No. 1 to Commercial License Agreement between Selexis SA and Oncternal Therapeutics, Inc., dated February 7, 2020 (Filed With SEC on March 16, 2020)

Amended Oncternal Therapeutics, Inc. Annual Incentive Plan (Filed With SEC on November 8, 2019)

Employment Agreement dated September 5, 2019 between Oncternal Therapeutics, Inc. and Hazel M. Aker (Filed With SEC on November 8, 2019)

Employment Agreement dated September 5, 2019 between Oncternal Therapeutics, Inc. and Richard G. Vincent (Filed With SEC on November 8, 2019)

Employment Agreement dated September 12, 2019 between Oncternal Therapeutics, Inc. and James B. Breitmeyer, M.D (Filed With SEC on November 8, 2019)

Employment Agreement dated September 9, 2019 between Oncternal Therapeutics, Inc. and Igor P. Bilinsky, Ph.D (Filed With SEC on November 8, 2019)

Employment Agreement dated September 5, 2019 between Oncternal Therapeutics, Inc. and Gunnar F. Kaufmann, Ph.D (Filed With SEC on November 8, 2019)

Employment Agreement dated August 26, 2019 between Oncternal Therapeutics, Inc. and Frank Hsu, M.D (Filed With SEC on November 8, 2019)

Specimen of Common Stock Certificate (Filed With SEC on August 9, 2019)

Form of Amendment to Warrant to Purchase shares of Series B-2 Preferred Stock of Oncternal Therapeutics, Inc (Filed With SEC on August 9, 2019)

Sublease by and between Oncternal Therapeutics, Inc. and Host Hotels & Resorts, L.P., dated May 22, 2019 (Filed With SEC on August 9, 2019)

CVR Agreement, dated as of June 7, 2019, by and between the Registrant, Marc S. Hanover, as the Holders Representative, and Computershare Investor Services, as Rights Agent (Filed With SEC on June 10, 2019)

Form of CVR Agreement by and between GTx, Marc S. Hanover, as the Holders Representative, and Computershare Investor Services, as Rights Agent (Filed With SEC on April 30, 2019)

License Agreement between Oncternal Therapeutics, Inc. and Velos Biopharma Holdings, LLC, dated February 6, 2018 (Filed With SEC on April 8, 2019)

Form of Warrant to purchase shares Series B-2 Preferred Stock of Oncternal Therapeutics, Inc (Filed With SEC on April 8, 2019)

Commercial License Agreement between Selexis SA (predecessor to Oncternal Therapeutics, Inc.) and ROAR Therapeutics, LLC, dated May 19, 2014 (Filed With SEC on April 8, 2019)

Exclusive License Agreement between Georgetown University and Oncternal Therapeutics, Inc., dated March 26, 2014 (Filed With SEC on April 8, 2019)

Amendment to Exclusive License Agreement between Georgetown University and Oncternal Therapeutics, Inc., dated March 17, 2016 (Filed With SEC on April 8, 2019)

Collaboration Agreement between Oncternal Therapeutics, Inc. and The University of Texas M.D. Anderson Cancer Center, dated December 15, 2014 (Filed With SEC on April 8, 2019)

Amendment #1 to Collaboration Agreement between Oncternal Therapeutics, Inc. and The University of Texas M.D. Anderson Cancer Center, dated January 24, 2016 (Filed With SEC on April 8, 2019)

Amendment #2 to Collaboration Agreement between Oncternal Therapeutics, Inc. and The University of Texas M.D. Anderson Cancer Center, dated May 1, 2016 (Filed With SEC on April 8, 2019)

Amendment #3 to Collaboration Agreement between Oncternal Therapeutics, Inc. and The University of Texas M.D. Anderson Cancer Center, dated September 17, 2018 (Filed With SEC on April 8, 2019)

Research agreement between Oncternal Therapeutics, Inc. and the Regents of the University of California, on behalf of its San Diego Campus, dated November 3, 2016 (Filed With SEC on April 8, 2019)

Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and The Regents of the University of California, dated August 31, 2018 (Filed With SEC on April 8, 2019)

Employment Letter dated January 1, 2019, between Oncternal Therapeutics, Inc. and Richard G. Vincent (Filed With SEC on April 8, 2019)

Oncternal Therapeutics, Inc. 2015 Equity Incentive Plan, as amended (Filed With SEC on April 8, 2019)

Form of Stock Option Agreement under the Oncternal Therapeutics, Inc. 2015 Equity Incentive Plan, as amended (Filed With SEC on April 8, 2019)

Form of Early Exercise Stock Option Agreement under the Oncternal Therapeutics, Inc. 2015 Equity Incentive Plan, as amended (Filed With SEC on April 8, 2019)

Restricted Stock Purchase Agreement dated May 22, 2017, between Oncternal Therapeutics, Inc. and Richard G. Vincent (Filed With SEC on April 8, 2019)

Restricted Stock Purchase Agreement dated December 14, 2017, between Oncternal Therapeutics, Inc. and Richard G. Vincent (Filed With SEC on April 8, 2019)

Restricted Stock Purchase Agreement dated December 14, 2017, between Oncternal Therapeutics, Inc. and William R. LaRue (Filed With SEC on April 8, 2019)

Restricted Stock Purchase Agreement dated May 9, 2018, between Oncternal Therapeutics, Inc. and Charles Theuer, M.D., Ph.D (Filed With SEC on April 8, 2019)

Employment Letter dated May 31, 2017, between Oncternal Therapeutics, Inc. and James B. Breitmeyer, M.D., Ph.D (Filed With SEC on April 8, 2019)

Amendment #1 to Amended and Restated License Agreement between Oncternal Therapeutics, Inc. and the Regents of the University of California, dated March 25, 2019 (Filed With SEC on April 8, 2019)

Consulting Agreement dated April 3, 2017, between Oncternal Therapeutics, Inc. and Richard G. Vincent (Filed With SEC on April 8, 2019)

Amendment #4 to the License Agreement, as amended, dated October 23, 2018, between the Registrant and University of Tennessee Research Foundation (Filed With SEC on March 18, 2019)

Amendment #2 to the License Agreement, as amended, dated August 12, 2016, between the Registrant and University of Tennessee Research Foundation (Filed With SEC on March 18, 2019)

Amendment #3 to the License Agreement, as amended, dated April 6, 2017, between the Registrant and University of Tennessee Research Foundation (Filed With SEC on March 18, 2019)

Amendment #1 to the License Agreement, dated November 12, 2015, between the Registrant and University of Tennessee Research Foundation (Filed With SEC on March 18, 2019)

License Agreement, effective March 1, 2015, between the Registrant and University of Tennessee Research Foundation (Filed With SEC on March 18, 2019)

Form of GTx Voting Agreement, dated March 6, 2019, by and between Oncternal, GTx and each of the parties named in each agreement therein (Filed With SEC on March 7, 2019)

Form of CVR Agreement by and between GTx, Marc S. Hanover, as the Holders Representative, and Computershare Investor Services, as Rights Agent (Filed With SEC on March 7, 2019)

Form of Oncternal Voting Agreement, dated March 6, 2019, by and between GTx, Oncternal and each of the parties named in each agreement therein (Filed With SEC on March 7, 2019)

Form of Lock-Up Agreement, dated March 6, 2019, by each of the parties named in each agreement therein (Filed With SEC on March 7, 2019)

Agreement and Plan of Merger and Reorganization, dated March 6, 2019, by and among GTx, Oncternal and Merger Sub (Filed With SEC on March 7, 2019)

GTX INC (85)